Drugs / Infanrix-IPV+Hib™
Infanrix-IPV+Hib™
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01577732 | Dec 2012 → Apr 2013 | diphtheria, haemophilus infectious disease, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Infanrix-IPV+Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01577732 ↗ |
| Known as | DTPa-IPV/Hib | “GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix-IPV+HibTM) in Healthy Vietnamese Toddlers” NCT01577732 ↗ |
| Known as | Infanrix-IPV+HibTM | “Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers” NCT01577732 ↗ |
| Modality | Vaccine | “Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers” NCT01577732 ↗ |
| Route | Intramuscular | “Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.” NCT01577732 ↗ |